Prevalence of Benign Prostatic Hyperplasia and Prostate Cancer Among Adults in Pakistan
DOI:
https://doi.org/10.70749/ijbr.v3i3.808Keywords:
Benign Prostatic Hyperplasia, Prostate Cancer, Prevalence, Adult MalesAbstract
Background: Benign Prostatic Hyperplasia (BPH) and prostate cancer are common prostate-related conditions affecting adult males, especially as they age. Both conditions are associated with various risk factors such as age, family history, smoking, and obesity. Objective: The aim of this study was to investigate the prevalence, risk factors, and diagnostic markers, specifically prostate-specific antigen (PSA) levels, among patients diagnosed with BPH and prostate cancer. Methods: This descriptive cross-sectional study was conducted at Institute of kidney diseases, Hayatabad, Peshawar during June 2022 to March 2023. A total of 125 patients were added in the study. Data for this study were collected through a combination of clinical evaluations, laboratory tests, imaging, and histopathological examinations. Demographic data were collected from each patient, including age, family history of prostate diseases, lifestyle habits, and dietary factors. Results: The prevalence of BPH was found to be significantly higher (64%) compared to prostate cancer (20%). The majority of patients with both conditions were aged 60 years and above. A family history of prostate disease was reported by 50% of prostate cancer patients, while 25% of BPH patients had a similar history. Elevated PSA levels were found in 70% of prostate cancer patients, with a mean PSA of 12.0 ng/mL, compared to 4.5 ng/mL in BPH patients. Smoking and obesity were identified as common lifestyle factors among both patient groups, with prostate cancer patients showing a higher incidence of these risk factors. Conclusions: It is concluded that Benign Prostatic Hyperplasia (BPH) and prostate cancer are prevalent conditions among adult males, with BPH being more common than prostate cancer in this study. Age, family history, smoking, and obesity were identified as significant risk factors for both conditions.
Downloads
References
Oyelekan A, Ogunsemi O, Afe T, Ayoade B, Nwokoro C, Oluyemi O, et al. Sleep quality and lower urinary tract symptoms among patients with prostatic diseases. Ann Afr Surg. 2020;17(2):69-71. https://doi.org/10.4314/aas.v17i2.6
Khan FU, Ihsan AU, Khan HU, Jana R, Wazir J, Khongorzul P, et al. Comprehensive overview of prostatitis. Biomed Pharmacother. 2017;94:1064-1076. https://doi.org/10.1016/j.biopha.2017.08.016
Repetto E, Sosa A, Colla R, Revol M, Metrebian E, Metrebian S. Relationship of prostatitis in the appearance of prostate cancer and benign prostatic hyperplasia. Revista Cubana de Urología. 2019;8(1):22-33.
Zhang L, Wang Y, Qin Z, Gao X, Xing Q, Li R, et al. Correlation between Prostatitis, benign prostatic hyperplasia and prostate cancer: A systematic review and meta-analysis. J Cancer. 2020;11(1):177-189. https://doi.org/10.7150/jca.37235
María Molero J, Miñana B, Palacios‐Moreno JM, Téllez Martínez‐Fornes M, Lorite Mingot D, Agra Rolán A, et al. Real‐world assessment and characteristics of men with benign prostatic hyperplasia (BPH) in primary care and urology clinics in Spain. Int J Clin Pract. 2020;74(11):e13602:1-12. https://doi.org/10.1111/ijcp.13602
Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. Sci Rep. 2017;7(1):7984:1-10. https://doi.org/10.1038/s41598-017-06628-8
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492
Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health. 2018;12(6):1807-1823. https://doi.org/10.1177/1557988318798279
Pakzad R, Mohammadian-Hafshejani A, Ghoncheh M, Pakzad I, Salehiniya H. The incidence and mortality of prostate cancer and its relationship with development in Asia. Prostate Int. 2015;3(4):135-140. https://doi.org/10.1016/j.prnil.2015.09.001
Idrees R, Fatima S, Abdul-Ghafar J, Raheem A, Ahmad Z. Cancer prevalence in Pakistan: meta-analysis of various published studies to determine variation in cancer figures resulting from marked population heterogeneity in different parts of the country. World J Surg Oncol. 2018;16(1):129-139. https://doi.org/10.1186/s12957-018-1429-z
Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol. 2016;11(1):25-32. https://doi.org/10.1186/s13000-016-0478-2
Rajani R, Mehta N, Goswami H. Histopathological study of prostatic lesions at tertiary care centre. Int J Clin Diagn Pathol. 2020;3(2):172-176. https://doi.org/10.33545/pathol.2020.v3.i2c.249
Dai X, Fang X, Ma Y, Xianyu J. Benign prostatic hyperplasia and the risk of prostate cancer and bladder cancer: a meta-analysis of observational studies. Med (Baltimore). 2016;95(18):3493:1-8.
Punjab Cancer Registry Report [Internet]. 2016 [cited 3 March 2020]. http://punjabcancerregistry.org.pk/reports/PCR_2016.pdf
Rasul G, Khan I, Jan MA, Ahmad T, Khattak IU, Aslam M. Frequency of incidental prostate cancer in patients presenting with palpable enlarged prostate gland. J Postgrad Med Inst. (Peshawar-Pakistan). 2019;33(3):210-215.
Muralidhar V, Ziehr DR, Mahal BA, Chen YW, Nezolosky MD, Viswanathan VB, et al. Association between older age and increasing Gleason score. Clin Genitourin Cancer. 2015;13(6):525-530. https://doi.org/10.1016/j.clgc.2015.05.007
Tanveer M, Tahir F, Majid Z, Hussain MM, Asghar SA, Qadar LT, et al. Awareness and self care practices of elderly men regarding prostate diseases in Karachi, Pakistan. Cureus. 2019;11(5):4617. https://doi.org/10.7759/cureus.4617
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
